What is Neurosteer?
Neurosteer has developed a medical-grade, pocket-sized brain activity interpretation platform, hdrEEG, designed for the early detection of neurological conditions such as Parkinson's, Alzheimer's, and epilepsy. Their innovative technology provides real-time analysis and objective biomarkers, enabling more accessible and effective treatment options. The platform supports both clinical applications and continuous remote monitoring, aiming to establish a new standard in brain health diagnostics for healthcare professionals and caregivers alike.
How much funding has Neurosteer raised?
Neurosteer has raised a total of $44K across 1 funding round:
Debt
$44K
Debt (2021): $44K with participation from PPP
Key Investors in Neurosteer
PPP
Public-Private Partnership
What's next for Neurosteer?
With significant Series B/C stage funding, Neurosteer is strategically positioned to scale its operations and further develop its hdrEEG platform. The recent influx of expansion capital suggests a focus on market penetration, potential product enhancements, and broadening the reach of its diagnostic capabilities. This investment will likely fuel research and development efforts, aiming to solidify Neurosteer's position as a leader in accessible and advanced neurological monitoring solutions.
See full Neurosteer company page
